Drugs / TER-1754
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07255846 | Dec 2025 → Mar 2028 | hereditary hemorrhagic telangiectasia | Terremoto Biosciences Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TER-1754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07255846 ↗ |
| Action | Inhibit | “a novel AKT1 inhibitor” NCT07255846 ↗ |
| Route | Oral | “QD or BID, orally in 28-day cycles” NCT07255846 ↗ |
| Target | AKT1 | “a novel AKT1 inhibitor” NCT07255846 ↗ |